SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.
Joshua A HillMichael J MartensJo-Anne H YoungKavita BhavsarJianqun KouMin ChenLik Wee LeeAliyah BaluchMadhav V DhodapkarRyotaro NakamuraKristin PeytonDianna S HowardUroosa IbrahimZainab ShahidPaul ArmisteadPeter WesterveltJohn McCartyJoseph McGuirkMehdi HamadaniSusan DeWolfKinga HosszuElad SharonAshley SpahnAmir A ToorStephanie WaldvogelLee M GreenbergerJeffery J AulettaMary M HorowitzMarcie L RichesMiguel-Angel PeralesPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
These data support mRNA SARS-CoV-2 vaccination prior to, and reinitiation 3 to 4 months after, cellular therapies with allogeneic HCT, autologous HCT, and CAR-T-cell therapy.
Keyphrases
- cell therapy
- sars cov
- bone marrow
- mesenchymal stem cells
- respiratory syndrome coronavirus
- stem cells
- stem cell transplantation
- cell cycle arrest
- electronic health record
- cross sectional
- cell death
- big data
- clinical trial
- double blind
- single cell
- hematopoietic stem cell
- high dose
- coronavirus disease
- data analysis
- cell proliferation
- signaling pathway
- pi k akt
- artificial intelligence